Compare INNV & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | NBTX |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | 2018 |
| Metric | INNV | NBTX |
|---|---|---|
| Price | $9.53 | $29.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $12.00 | ★ $54.00 |
| AVG Volume (30 Days) | ★ 576.2K | 141.6K |
| Earning Date | 11-03-2026 | 09-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $989,707,000.00 | N/A |
| Revenue This Year | $8.51 | N/A |
| Revenue Next Year | $7.99 | $50.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.93 | N/A |
| 52 Week Low | $3.94 | $14.78 |
| 52 Week High | $12.64 | $57.14 |
| Indicator | INNV | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 54.80 |
| Support Level | $7.54 | $20.18 |
| Resistance Level | $12.05 | $35.38 |
| Average True Range (ATR) | 0.28 | 1.51 |
| MACD | 0.12 | 1.10 |
| Stochastic Oscillator | 76.37 | 94.47 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.